Top of the page.
Skip the menu to main contents.
Move to main menu.
Skip to main contents.

Main menu starts here.
Skip the main menu to current location in your website.

Current location in your website.
Skip to main contents.

Inflammatory Field


Toyama Chemical also conducts research in the development of anti-inflammatory agents for diseases such as rheumatoid arthritis (RA) and osteoarthritis. These are more than 0.7 million patients with RA in Japan, and 6.5 million overseas. Recently, several new drugs show the strong efficacy in RA patients, but they have some important problems like serious adverse effects, and so on. Toyama Chemical collaborates with organizations in Japan and overseas for efficiency in development of new drugs.

Subjects of research


Iguratimod, anti-rheumatic agent, was discovered by the Research Laboratories of Toyama Chemical.
Through the latest findings of iguratimod's mode of action, Toyama Chemical is investigating its further potential of new applications in the inflammatory field.

Related Information

Main business fields that TOYAMA CHEMICAL concentrates.

Footer starts here.

Pages ends here.
Move to top of the page.